Teva Pharma (TEVA) PT Lowered to $64 at Mizuho; 'Buy' Maintained
- Stock futures rise as flurry of deal activity boosts confidence
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- TD Ameritrade (AMTD) to Acquire Scottrade in $4B Cash & Stock Deal
- Oil prices fall as Iraq resists joining output cut
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities analyst Irina Koffler lowered her price target on Teva Pharma (NYSE: TEVA) price to $64.00 (from $70.00) following a negative IPR decision on two Copaxone patents but maintained a Buy rating. The analyst has gotten more conservative in their outer year expectations.
Koffler commented, "Our Buy thesis is predicated on valuation rather than any particular catalyst, though additional visibility into the recently acquired generics business and pipeline could serve to drive share momentum in 2H:16."
Shares of Teva Pharma closed at $51.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Teva Pharma (TEVA) to Neutral
- Deutsche Bank Upgrades CarMax (KMX) to Buy
- Deutsche Bank Downgrades Brown & Brown (BRO) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!